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Abstract
Background: The management of patients with heart failure (HF) needs to account for changeable and complex individual
clinical characteristics. The use of renin angiotensin system inhibitors (RAAS-I) to target doses is recommended by
guidelines. But physicians seemingly do not sufficiently follow this recommendation, while little is known about the
physician and patient predictors of adherence.
Methods: To examine the coherence of primary care (PC) physicians’ knowledge and self-perceived competencies regarding
RAAS-I with their respective prescribing behavior being related to patient-associated barriers. Cross-sectional follow-up
study after a randomized medical educational intervention trial with a seven month observation period. PC physicians
(n=37) and patients with systolic HF (n=168) from practices in Baden-Wuerttemberg. Measurements were knowledge
(blueprint-based multiple choice test), self-perceived competencies (questionnaire on global confidence in the therapy and
on frequency of use of RAAS-I), and patient variables (age, gender, NYHA functional status, blood pressure, potassium level,
renal function). Prescribing was collected from the trials’ documentation. The target variable consisted of $50% of
recommended RAAS-I dosage being investigated by two-level logistic regression models.
Results: Patients (69% male, mean age 68.8 years) showed symptomatic and objectified left ventricular (NYHA II vs. III/IV:
51% vs. 49% and mean LVEF 33.3%) and renal (GFR,50%: 22%) impairment. Mean percentage of RAAS-I target dose was
47%, 59% of patients receiving $50%. Determinants of improved prescribing of RAAS-I were patient age (OR 0.95, CI 0.92–
0.99, p=0.01), physician’s global self-confidence at follow-up (OR 1.09, CI 1.02–1.05, p=0.01) and NYHA class (II vs. III/IV) (OR
0.63, CI 0.38–1.05, p=0.08).
Conclusions: A change in physician’s confidence as a predictor of RAAS-I dose increase is a new finding that might reflect an
intervention effect of improved physicians’ intention and that might foster novel strategies to improve safe evidence-based
prescribing. These should include targeting knowledge, attitudes and skills.
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Introduction
Heart failure (HF) remains a deadly and costly, however
treatable disease [1–3]. The clinical management of HF is
complex and includes a repeated evaluation of the clinical course
of the syndrome and its’ comorbidities. Moreover it encompasses
patient education, non-/pharmacological treatment, devices and
surgery. Thus a coordinated and transdisciplinary approach is
mandatory. Evidence-based pharmacological treatment, such as
the use of renin angiotensin aldostererone inhibitors (RAAS-I) and
betablockers (BB) requires the physician’s competence in prescrib-
ing appropriate medications (indications vs contraindications) and
step-wise up-titration while monitoring typical side-effects (i.e.
hypotension, change in creatinine-clearance or potassium levels)
during the subsequent trajectory of the syndrome [4–8].
Despite the consensus on clinical practice guidelines (CPG) that
recommend the use of RAAS-I in target doses [8–10], there seems
to be imperfect transfer into practice, especially in primary care.
Current literature suggests that many patients actually, do not
receive RAAS-I, mostly due to clinical and/or professional
uncertainty or unawareness [11]. If prescribed, doses were titrated
to only 50% of the target doses recommended in the CPGs
[11,12]. Understanding this gap between a physician’s knowledge
and his actual acting might therefore be essential for the
development of strategies aiming to improve the care of HF
patients [13].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31082In general, reasons for non-adherence to guideline recommen-
dations can either be attributed to the knowledge and attitudes of
physicians or might be due to external factors like specific
reimbursement procedures or patient preferences [14]. Self-
reported physician-related barriers to evidence based prescribing
of HF medication include lack of knowledge or confidence [15–
18], but these do not explain variance in treatment alone [18].
Usually, physician characteristics, as part of explorative studies,
have been shown to impact the quality of care the patients receive.
For example, working individually more than 15 years as a
primary care physician has been correlated with non-prescription
of RAAS-I [19]. Moreover a comparison between specialties
revealed that primary care physicians use less diagnostic
procedures and less evidence-based pharmacotherapy which was
found to be explained only in part by patient characteristics [20].
However, many patients with heart failure have comorbidities
that would have prevented inclusion in RCTs that have shown
benefits in mortality [21], which reflects the complexity physicians
face (especially in primary care) in the treatment of elderly,
multimorbid patients [22]. Patient characteristics that have been
found to be associated with the prescription of RAAS-I are age
[12,19,23], gender [23], NYHA functional class [24] and
comorbidity, such as hypertension [19,24] and renal failure [12].
Even organizational aspects of health care systems may impact on
prescribing patterns [25], irrespective of variations in guideline
recommendations across Europe [26].
In order to explore the effect of physician and patient factors on
RAAS-I dosage in patients with systolic heart failure, we used
data collected as part of the Train-the-Trainer (TTT) trial
(ISRCTN08601529) that compared the effectiveness of two
specific medical education interventions for primary care physi-
cians [27,28]. Clinical trial design and data quality (with a pre-
specified population of patients with systolic heart failure) offered
the opportunity to study target dosing in the context of medical
education. Results of the TTT trial showed that a multidisciplin-
ary, complex intervention is superior to a single lecture focusing on
evidence-based prescribing [27] as far as guideline adherence is
concerned.
We therefore aimed to examine the interrelation of physician’s
knowledge and self-perceived competencies regarding RAAS-I as
well as known patient-related barriers in clinical management with
the actual practice of prescribing RAAS-I to HF patients further
elucidating the individual impact of these factors.
Methods
The Train-the-Trainer trial was a cluster-randomized multifac-
eted CPG implementation trial aimed at improving quality of life
(QoL) of patients with HF by a mixed educational intervention for
primary care physicians [27,28]. After recruitment of physicians
and enrolment of eligible patients and baseline patient assessment,
physicians were randomized to either the intervention comprising
multiple educational sessions plus pharmacotherapy feedback
(TTT) or a lecture (Standard). After seven months (follow-up) a
second patient assessment took place. The trial conformed to the
principles outlined in the Declaration of Helsinki and was
registered (ISRCTN08601529).
Study Design and Objectives
As part of the pre-specified evaluation of the secondary
outcomes, self-perceived competencies (at baseline and at follow-
up, i.e. one and seven months after randomization) and care-
specific knowledge (at a seven month follow-up only) were assessed
(see Figure 1). Our objective was to explore the simultaneous
influence of pre-specified physician and patient factors on RAAS
inhibitor dosage in a post-interventional cross-sectional design.
Furthermore, the influence of distinct baseline variables was
examined to verify the results (see Figure 1).
Participants
Physicians were eligible for participation if they were certified as
a primary care physician and practised as a SHI (statutory health
insurance)-affiliated physician [28]. They recruited eligible
patients using provided screening algorithms for case finding in
electronic medical records. Eligibility criteria were adults (aged
over 40 years) with left- or biventricular heart failure, NYHA
functional class II–IV, with confirmed ejection fraction of 40% or
less (e.g. by echocardiography), with stable symptoms at
enrolment, and diagnosis of a chronic, irreversible HF at least 3
months prior to inclusion. We excluded patients with primary
Figure 1. Trial design. (in chronological order:) Patient enrolment by primary care physicians and baseline clinical documentation (patient
assessment), randomisation of physicians (with patients in clusters), physician self-assessment of competencies before (first) medical education
intervention (either TTT or Standard), second physician self-assessment before unheralded knowledge test, follow-up patient assessment.
doi:10.1371/journal.pone.0031082.g001
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diomyopathy (HOCM/RCM), and people with a concomitant
terminal illness, dementia or severe psychological illness. All
participants gave written informed consent [28].
After an initiation visit, physicians collected and documented
clinical data (general and cardiovascular history, actual clinical
status, lab and other results, detailed medication, etc.) in case
report forms (CRF) in their offices. They rated NYHA functional
class according to the provided definition, and they documented
aetiology, left ventricular ejection fraction (LVEF) or (if applicable)
comorbidities from cardiologist and other specialist reports.
Accordingly, to retrieve an estimate of patients’ ‘‘morbidity
burden’’ in addition to the documentation of single co-occurring
medical conditions, physicians applied the Cumulative Illness
Rating Scale (CIRS-G) [29] that measures the chronic medical
illness (‘‘morbidity’’) burden while taking into consideration the
severity of chronic diseases in 14 items representing individual
body systems. The final score of the CIRS is the sum of each of the
14 scores, a higher score indicating higher impairment [range 0–
56]. Actual laboratory results including creatinine and potassium
were also recorded. We estimated the creatinine clearance using
the formula by Cockroft and Gault [30]. Physicians documented
prescribed drugs and daily doses in detail allowing further
derivations. CRFs underwent a query management providing
high data quality as part of the trial [28].
Physicians received their educational interventions at the
medical university. Self-perceived competencies were assessed
twice, before the (first) educational session and before an
unheralded knowledge assessment that took place one month
before follow-up (see Figure 1).
Medical educational interventions
A framework guided us in the development of the educational
interventions [31] which was based on a problem identification
and general needs assessment [11,17,32] and a specific ‘‘needs
assessment of targeted learners’’ (publication in preparation) and
finally along the HF CPG [8].
The identified crucial topics of desired improvement, e.g.
indication and management of evidence-based pharmacotherapy,
detection and management of somatic psychological comorbid
disorders, communication and organisational skills were formu-
lated as specific learning goals (step 3). Both educational
interventions were based on the same learning goals and included
all relevant aspects of heart failure (epidemiology, definition,
classification, diagnostic, therapeutic and management aspects of
systolic and diastolic heart failure) and relevant psychosomatic
aspects (comorbid depressive disorders and anxiety, health-related
quality of life, and compliance). However, the educational
methods, the intensity and the educators involved differed (details
are reported elsewhere) [28]. This mix of methods, intensity and
educators was part of the development and tailoring and due to
the main intention of the project, i.e. improving health-related
quality of life of patients with HF, an ambitious goal that was
based on the assumption of ‘‘plenty’’ room of improvement in the
care of patients [28]. Physicians from the Standard group received
the CPG and a three-hour state-of-the-art lecture by a senior
cardiologist with didactic expertise (AR). Physicians in the TTT
group received a didactic (using different didactic formats),
repeated (four sessions) and interdisciplinary (primary care
physician, cardiologist and psychosomatic specialist: FPK, AR
and TMT) educational intervention with a total duration of
16 hours (see Figure 1). Additionally, the TTT group received a
pharmacotherapy feedback on the individual level of patients
participating in the trial (from data of the baseline documentation)
in the last session in month 6 [27].
Procedures and Investigations
Outcome variable. Assessment of adherence to recommen-
dations regarding RAAS-inhibitors was based on the current
national clinical practice guideline that was used in the educational
intervention [6–8] with minor national variations concerning
substances (**, see below) and daily target doses due to differences
in comparison to the European guidelines [4] [33]. The
recommendations by product information were congruent with
the guideline recommendations with the exception of Lisinopril
(10 mg) and Losartan (100 mg in case of concomitant
hypertension). In these cases, we decided to adhere to the
guideline recommendation, because we wanted to assess the
adherence to the guidelines, not to the product information.
Substances were (daily target doses in brackets): ACE-inhibitors
(ACE-I): Captopril (150 mg), Enalapril (20 mg), Lisinopril
(20 mg), Ramipril (10 mg), Trandolapril (4 mg), Benazepril
(20 mg)**, Fosinopril (35 mg)**, and Perindopril (4 mg)**.
Angiotensin receptor blockers (ARB): Candesartan (32 mg),
Valsartan (320 mg), and Losartan (100 mg)**.
Determinants. Our choice of variables to be analysed with
respect to their predictive value was based on the literature and
clinical expert experience [12,15–19,23,24]: Considering the
sample size we took pre-specified potential determinants, eight
patient-related (i.e. patient age, gender, NYHA functional class at
baseline, systolic and diastolic blood pressure, potassium level and
creatinine clearance at follow-up, CIRS-G sum score [29] as
measure for comorbidity and intervention group (Standard vs.
TTT)), three physician-related variables (specific knowledge score
[range 0–7], self-assessed frequency of prescription of RAAS-I
[range 1–5] and global self-confidence in therapy of HF [range 0–
100]).
The intervention team formulated multiple choice questions
(MCQ) according to a blueprint accounting for the rules for fair
and valid MCQ [34]. Depending on their contextual focus and
origin, the formulation of the MCQ was assigned to the
cardiologist and primary care researcher or to the psychosomatic
specialist and primary care researcher. After panel pre-review, the 40
most appropriate questions from the 58 MCQ in the original
version remained for the assessment: one correct answer
represented one point. The ratio of cardiologic to psychosomatic
MCQ remained 3 to 1. After the MCQ-test at the educational
workshop, the MCQ were analysed in a panel post-review process for
item difficulty, reliability and discriminative power. We pre-
specified to allow only MCQ with a minimum discriminative
power of r9.0.2 to remain in the test to shape the outcome
measure to a valid, reliable and discriminative instrument (for
details see Appendix S1). The application of objective criteria
resulted in 26 remaining questions for final evaluation (20 with
cardiologic and 6 with psychosomatic focus). The type of MCQ
was ‘‘single best answer’’. Cronbachs alpha of the overall MCQ-
test with 26 questions (after the pre-specified item-reduction from
40 to 26) was 0.76 (, for the first 0.66). The subgroups of
cardiologic and psychosomatic MCQ had a Cronbachs alpha of
0.72 and 0.58, respectively. To further focus on knowledge related
to the use of RAAS inhibitors, we selected those 7 of the 20
cardiologic questions that were obviously related to this aspect,
resulting in a specific knowledge score [0–7] (see also Appendix
S1).
A self-developed questionnaire for self-perceived competency in
the care of patients with HF was used. The questionnaire followed
main learning objectives and included the self-rated frequency of
Predictors of Prescribing in Heart Failure
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1–5, with low scores indicating a higher frequency or self-
confidence. Participants were also asked to rate their overall
confidence within the therapeutic domain of HF care using a visual
analogue scale (VAS) [0–100], higher sores indicating a higher
confidence. Participants completed this questionnaire before the
(first) educational interventions at the medical university and
before the knowledge assessment that took place at month seven
(one month before patient follow-up, for illustration see Figure 1).
Ethics
Ethical approval for the study was obtained from the
institutional review boards of the medical faculty of the University
of Heidelberg (252/2004) and of the medical association of the
state of Baden-Wuerttemberg (M-049-05-f). Written informed
consent was obtained from participating physicians and patients.
Statistical methods (if applicable)
A logistic regression model was used for the outcome variable
dosing of recommended RAAS inhibitors as the distribution of
mean percentages of doses did not allow a linear model.
Therefore, we treated the outcome variable as a dichotomous
variable with (cut-off $50% of target dose). Dummy variables
were built for ordinal variables (e.g. self-perceived confidence). We
aggregated NYHA functional class I with II and III with IV
accounting for the low number of observations in the classes I and
IV. For the regression model, we imputed missing data using
means of available data regarding self-rated frequency of
prescription and overall self-confidence in therapy, in both there
were missings in six cases. The model accounted for hierarchical
clustering of the data, with patient variables and the outcome
variable on level-1 and physician variables on level-two. The first
model was validated by excluding variables with a p-value greater
than 0.3. In other models, we replaced self-perceived competency
variables measured at follow-up by those at baseline to verify
further their predictive value. We used SPSS 15 for the analysis of
descriptive data and SAS 9.2 (PROC GENMOD) for the two-level
logistic regression analyses. As SAS outputs are reported in log
odds ratios, we transformed these in odds ratios for better
readability of the results.
Results
Physician and patient characteristics
Figure 2 shows the flow of participating physicians and patients
through the trial. Of the 750 physicians approached in a single
mail-out, 37 ultimately participated and recruited 168 eligible
patients between March and September 2005. Following patient
recruitment, 18 physicians were randomised to the TTT group
and 19 to the Standard group. At the patient level, 15 patients
were lost to follow up (13 died and 2 were lost during the follow
up). Therefore, for the outcome measure (dosage of recommended
RAAS inhibitors) 153 (91%) patients were analysable.
Participating physicians were mainly male (81%), had a mean
age of 50 and had on average been practicing as a primary care
physician for 15 years (Table 1). They were practicing in
individual practices in 46%, located in rural areas in 59%, and
had a list size of less than 1500 per quarter in 59%.
Figure 2. Flow of physicians and patients through the trial.
doi:10.1371/journal.pone.0031082.g002
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age was 68.8 years (Table 2). Table 2 shows patient characteristics,
including NYHA functional class (II: 51% vs. III/IV: 49%) and a
moderately impaired systolic function (LVEF 3367%). In 44% of
the cases coronary heart disease was the main cause for HF.
Different medical conditions were prevalent, e.g. atrial fibrillation
(19.6%), peripheral arterial disease (17.2%), COPD (19.6%) and
Depression (23.2%). Others were diabetes (36.3%), hypertension
(76.2%), and dyslipidemia (21.5%). Renal function was impaired
in 23.8% of cases (GFR,50 ml/min). Mean (SD) potassium levels
were 4.3 mmol/l, with 4 (2.4%) patients with hyperkalemia. Mean
systolic and diastolic blood pressures were 131 and 77 mmHg.
Physician-rated mean (SD) multimorbidity as indicated by CIRS-
score was 23.4 (5.6). Most patients were treated with ACE
inhibitors or angiotensin receptor blockers (90%), b-blockers
(79%), aldosterone antagonists (29%), and many other drugs (see
Table 2).
Target variable and physician determinants
The mean (SD) percentage of daily target dose at follow-up for
recommended RAAS-I was 47.0% (33.0), resulting in 90 patients
(58.8%) that received equal or above 50% of recommended daily
target doses.
Physicians’ scores were in mean (SD; range) regarding specific
knowledge 4.3 (1.4; 1–7) (n=37), global self-confidence in the
therapy at follow-up 79.2 (8.2; 66–92) (n=37), and in frequency of
and confidence in use of RAAS-I 1.4 (0.4; 1–2) and 1.6 (0.6; 1–3)
(both n=31).
For further results regarding between group comparisons see
Appendix S1, table 4. Furthermore, participants evaluated both
interventions with high levels of satisfaction (see Appendix S1,
table 5).
Predictors of prescribing
Patient age was the only patient-related variable with significant
impact on dosing of recommended RAAS-I at follow-up. Patients
with a higher age were less likely to be prescribed RAAS-I at doses
of equal or more than 50% of target doses (odds ratio 0.95; 95%
CI 0.92–0.99; p-value: 0.01). NYHA functional class showed a
trend, i.e. patients with a higher NYHA class were less likely
prescribed higher doses (odds ratio 0.63; 95% CI 0.38–1.05; p-
value: 0.08) (see Table 3).
Physician-related variables showed a potential impact of specific
knowledge (related to pharmacotherapy), i.e. physicians with
higher knowledge scores were less likely to prescribe higher doses
(odds ratio 0.81; 95% CI 0.62–1.17; p-value: 0.11), this result,
however, was not statistically significant. In contrast to self-assessed
frequency, the global self-confidence in therapy of HF had a
significant impact, i.e. the higher the global self-confidence, the
higher were observed prescribed doses (odds ratio 1.09; 95% CI
1.02–1.05; p-value: 0.01) (see Table 3).
Neither multimorbidity (as measured by CIRS summary score)
nor systolic/diastolic blood pressure, or renal function, or
hyperkalemia were associated with prescription of higher doses
of RAAS inhibitors (data not shown). So were neither global self-
confidence in therapy, nor frequency of or confidence in the use of
RAAS-I at baseline (data not shown).
Discussion
Summary of main findings
Optimizing evidence-based prescription in HF care is widely
accepted as an appropriate and common performance measure.
This study focused on primary care physicians’ competency levels
(before and after attending a CME event) and patient-related
barriers as predictors of actual guideline-conform prescription of
ACE inhibitors or angiotensin receptor blockers (RAAS inhibitors)
at daily doses equal or more than 50% of target. Physicians’ global
self-confidence in therapy of HF positively determined while
patient age negatively determined RAAS-I prescription towards
target dose. Outcome-specific factual knowledge and a higher
NYHA functional class showed a trend for a negative impact.
Table 1. Baseline characteristics of all 37 participating primary care practices.
Physician and practice factors at baseline TTT group (n=18) Control group (n=19)
Female PCPs 3 (17) 4 (21)
Age of PCP in years (SD) 50 (9.4) 50 (5.9)
Certification of PCP since years (SD) 16 (11.4) 15 (7.2)
No. of PCPs (whole time equivalent)
Single 9 (50) 11 (57.9)
Two 8 (44.4) 5 (26.3)
More than two 1 (5.6) 3 (25.8)
Location of practice
Rural 13 (72.2) 9 (47.4)
Suburban 2 (11.1) 4 (21.1)
Urban 3 (16.7) 6 (31.6)
List size (patients per quarter)
0–999 6 (33.3) 3 (15.8)
1000–1499 5 (27.8) 8 (42.1)
.1499 7 (38.9) 7 (36.8)
Participation in disease management programmes or quality circles 17/18 (94.4/100) 19/18 (100/94.7)
Values represent number (percentages) of physicians unless stated otherwise.
PCP: Primary Care Physician.
doi:10.1371/journal.pone.0031082.t001
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The fact that the parental trial was performed as a clinical trial
promoted the internal validity [28]. For example, the defined
patient population with confirmed symptomatic systolic heart
failure is an essential aspect to assess evidence-based pharmaco-
therapy such as target dosing of RAAS-I. Similarly, patient
variables derived from the trial documentation are characterized
by a high validity. However, although developed with considerable
time and effort, assessment of physician-related competence lacks
validation and the study is relatively small in size which probably
questions its power to detect significant predictors and to detect
between group differences (see Appendix S1, table 4 competence
outcomes).
A physician participation rate of 5% (see Figure 2) and some
physician and patient characteristics may indicate that participants
are not representative of the primary care physicians’ population:
‘‘High time and effort’’ due to the trial’s documentation and lack
of eligible patients (both measures for a high internal validity) were
the main reasons for the non-participation of physicians.
Physicians’ offices were larger than average (approx. 800/practice)
and had a larger adoption rate of primary care-based disease
management programs and peer review groups (approx. 53 and
30%). Baseline prescription rates of RAAS-I and betablockers
revealed a superior guideline adherence as compared to other
primary-care based studies, while being similar in comparison to
studies conducted in secondary care [35,36]. In our view, the
observation of high prescription rates is rather based on the
inclusion criterion of objectified systolic heart failure than a selection
bias as it is the crucial indication to start RAAS-I. As primary-
care-based studies in HF typically lack a predefined population (of
systolic HF patients) prescribing rates are therefore lower. In fact,
results of a primary care-based dutch study (10.6% confirmed
systolic heart failure) suggest that an objectified systolic HF
diagnosis, specific care in an HF clinic or referrals to a cardiologist
are all associated with the prescription of ACE inhibitors [23].
General interpretation in the context or current evidence
The understanding of how physician- and patient-related
characteristics are associated with target dosing may foster future
(educational) efforts to improve care. Some results are in line with
previous findings such as age [12,19,23] and female gender being a
negative patient-level predictor. We cannot explain the (non-
significant) finding that a high NYHA score negatively determined
Table 2. Patient characteristics at baseline for groups
(n=168).
TTT
(n=91)
Standard
(n=77)
Male sex 63 (69.2) 53 (68.8)
Mean (SD) age (years) 68.4 (10.6) 69 (9.5)
Living alone 27 (29.7) 22 (28.6)
NYHA-functional class
(according to GP)
II 44 (48.4) 41 (53.3)
III 46 (50.6) 33 (42.9)
IV 1 (1) 3 (3.9)
Mean (SD) LVEF 32.5 (7.1)
(n=79)
34.4 (6.5)
(n=64)
Ischemic Etiology 43 (47.3) 31 (40.3)
Mean (SD) duration
(years) of CHF
5.6 (4.9) 5.8 (5.6)
Medical conditions
Atrial fibrillation 21 (23.1) 12 (15.6)
PAD 15 (16.5) 14 (18.2)
Cerebrovascular disease 18 (19.8) 14 (18.2)
COPD 18 (19.8) 15 (19.5)
Depression 22 (24.2) 17 (22.1)
Cardiovascular risk factors
Diabetes mellitus 32 (35.2) 29 (37.7)
Hypertension 68 (74.7) 60 (77.9)
Dyslipidemia 68 (74.7) 60 (77.9)
Creatinine-Clearance: Mean
(SD) GFR (ml/min)*
74.1 (31.7) 66.5 (27.4)
GFR,50 ml/min 19 (20.9) 18 (23.4)
GFR,20 ml/min 2 (2.2) 1 (1.3)
Mean (SD) Kalium (mmol/l) 4.3 (0.6) 4.4 (0.5)
Hyperkalemia (K.5.5 mmol/l) 3 (3.3) 1 (1.4)
Mean (SD) Systolic Blood Pressure 130.9 (20.6) 130.2 (19.3)
Mean (SD) Diastolic Blood Pressure 76.7 (11.3) 76.1 (8.6)
Mean (SD) Comorbidity (CIRS-G)** 24.2 (6.0) 22.5 (4.8)
Drugs at baseline included:
ACE inhibitor 69 (75.8) 61 (79.2)
ARB 15 (16.5) 10 (13.0)
ACE inhibitor or ARB 83 (91.2) 68 (88.3)
b-blocker 71 (78.0) 62 (80.5)
ACE inhibitor or ARB and
b-blocker
65 (71.4) 57 (74.3)
Spirononolactone/Eplerenone 29 (31.9) 19 (24.7)
Loop diuretic 55 (60.4) 47 (61.0)
Thiazide diuretic 38 (41.8) 26 (33.8)
Cardiac glycoside 32 (35.2) 32 (41.6)
Nitrates (any) 17 (18.7) 12 (15.6)
Calcium channel blocker 9 (9.9) 7 (9.1)
Antiarrhythmic agents 8 (8.8) 5 (6.59
Aspirin 32 (35.2) 37 (48.1)
Statin 47 (59.7) 47 (51.6)
Oral anticoaculant 51 (56.0) 31 (40.3)
TTT
(n=91)
Standard
(n=77)
Insulin (any) 8 (8.8) 14 (18.2)
Oral antidiabetic 22 (24.2) 15 (19.5)
Values are numbers (percentages) of all patients unless stated otherwise.
NYHA, New York Heart Association; LVEF, Left ventricular ejection fraction; CHF,
Chronic (systolic) heart failure; CHD, Coronary heart disease; PAD, Peripheral
arterial disease; COPD, Chronic obstructive pulmonary disease.
*Estimation of the GFR according to the formula by Cockroft and Gault;
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker.
**CIRS-G, Cumulative illness (physician) rating scale, range 0–56, lower scores
imply less impairment of 14 body systems.
Patient variables in bold were selected for the verification of their role as
determinants of prescribing.
doi:10.1371/journal.pone.0031082.t002
Table 2. Cont.
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showed that with higher NYHA scores the rates of ACE inhibitors
increased [24]. This study, however, is not easy to compare as
rates of ACE inhibitor prescription were high in our study and
studies chose different outcomes (prescription versus target dosing
rates). The patient population of the IMPROVEMENT survey
shows another spectrum of patients, it was less defined regarding
the left ventricular systolic dysfunction (LVEF,40% in 33% of
patients in Germany and 27% in all countries) with another
morbidity pattern of asymptomatic (12%), mild (34%), moderate
(31%) and severe (10%) symptoms (percentages are given for the
overall population). Therefore, in that study, NYHA stage in that
population might indirectly reflect the type and advanced stage of
heart failure, which, once assessed and confirmed crucially guide
physicians’ treatment decisions.
More interestingly, global self-confidence in the therapy of HF
after (but not so prior to!) a CME event predicted target dosing,
while conversely knowledge seemed to do the opposite. The first
aspect is in line with literature that suggests that training may
reduce variation between self- and external assessments [37–39],
but the second is difficult to interpret: Qualitative studies suggest
that increased confidence is associated with greater self-reported
prescribing rates of ACE inhibitors [16]. It may be speculated that
knowing more specific facts by itself increases the awareness of
iatrogenic effects and might therefore induce reluctance in some
physicians to increase the dose in elderly patients (primum nihil
nocere!). This is reflected by various authors showing that primary
care physicians did not use ACE inhibitors because of fear of side
effects [15,16,40]. Psychological and organisational theory is being
used to explain and to influence professional behaviour and might
be helpful in relation to our findings, although there are virtually
innumerable theories and constructs, without any final theory or
model whatsoever [41–49]. Nevertheless, physicians’ (post-inter-
ventional) self-confidence in our study might reflect the compe-
tence, motivation, and intention finally to prescribe higher
dosages. Of note, it might also depend on personality traits as
some physicians may have hesitated to use their newly acquired
knowledge in case of elderly patients. However, our study did not
identify objective predictive patient-related factors that reflect
intolerance of up-titration. Therefore, final causal relations of this
observation remain unclear.
Sinha et al. investigated physician characteristics in the
context prescription of beta-blockers among patients with
systolic HF, another important evidence-based treatment [50]:
In their cross-sectional survey with a supplementary retrospec-
tive chart review they examined the association between primary
care physician characteristics and both self-reported and actual
prescription, results showed that physicians with teaching
responsibilities and physicians with confidence in managing
HF patients reported significantly higher rates of beta-blocker
prescribing. However, only self-reported rates of prescribing
were significantly associated with actual prescribing of beta-
blockers among HF patients, not other physician characteristics,
and the authors discussed a lack of power for further
discrimination of the explanatory variables. Nevertheless, they
concluded that self-confidence seems to play a role in beta-
blocker prescribing in HF and should be targeted by teaching.
Insofar the results of our study are in line with Sinha et al. and
might be even stronger as they show the association of self-
confidence and actual prescription.
Limitations
Usually, determinants of evidence-based prescribing rely on
explorative, secondary studies, which was the case in our study.
However, our study has several limitations: It is relatively small in
size, which prohibits further explanatory variables, whether
physician- or patient-related [12,19,23,24], or related to the
organization of care [23]. As we were especially interested in the
predictive role of different levels of physicians’ competencies, we
focused on these pre-specified variables while taking account for
variables that play a direct role in medical decision making in this
context. Further limitations are the use of self-developed and not
completely validated assessments of physicians’ competence. The
use of imputation methodology in six observations might have
affected the internal validity. Finally, the focus of this paper was
not a primary outcome of the parental trial.
Conclusions
Our findings replicated known barriers (such as patient age) to
the prescription of RAAS-inhibitors according to actual guideline
recommendations. Physicians’ self-confidence and factual knowl-
edge improved after the educational interventions, but only self-
confidence became predictive of prescribing behaviour which
might reflect an intervention effect of improved physicians’
intention. Therefore, educational approaches that target knowl-
edge, skills and attitudes (e.g. intentions) are required to further
close the perceived performance gaps in complex behaviours such
Table 3. Predictors of prescribing of ACE inhibitor or angiotensin receptor blocker (RAAS inhibitor) conforming with guideline
recommendations at follow-up (n=153).
Predictors of the final model
RAAS inhibitor $50% of daily target dose
Odds ratio (95% CI), p-value*
Intercept 0.25 (0.00–145.15), 0.67
Treatment group (TTT vs. Standard) 0.63 (0.25–1.60), 0.33
Age 0.95 (0.92–0.99), 0.01
Gender (female vs. male) 0.68 (0.32–1.45), 0.32
NYHA functional class** 0.63 (0.38–1.05), 0.08
Specific knowledge related to pharmacotherapy (MCQ test)** 0.81 (0.62–1.17), 0.11
Self-assessed frequency of prescription of ACE inhibitors** 1.52 (0.64–3.64), 0.34
Self-assessed global self-confidence in therapy of CHF (VAS)** 1.09 (1.02–1.05), 0.01
*according to a two-level logistic regression model using PROC GENMOD accounting for clustering of the data.
**at follow-up.
doi:10.1371/journal.pone.0031082.t003
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failure. Further theory-driven research with comprehensive
assessments using validated instruments and a larger dataset and
sample is also recommended to further clarify the mechanisms of
knowledge transfer into daily practice.
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